PT - JOURNAL ARTICLE AU - Bremova-Ertl, Tatiana AU - Abel, Larry AU - Walterfang, Mark AU - Salsano, Ettore AU - Ardissone, Anna AU - Malinová, Věra AU - Kolníková, Miriam AU - Bayarri, Jordi Gascón AU - Tavasoli, Ali Reza AU - Ashrafi, Mahmoud Reza AU - Amraoui, Yasmina AU - Mengel, Eugen AU - Kolb, Stefan A. AU - Brecht, Andreas AU - Bardins, Stanislavs AU - Strupp, Michael TI - Ocular motor biomarkers in Niemann-Pick disease type C: A prospective cross-sectional multicontinental study in 72 patients AID - 10.1101/2020.08.05.20158915 DP - 2020 Jan 01 TA - medRxiv PG - 2020.08.05.20158915 4099 - http://medrxiv.org/content/early/2020/08/11/2020.08.05.20158915.short 4100 - http://medrxiv.org/content/early/2020/08/11/2020.08.05.20158915.full AB - Niemann-Pick type C (NPC) is a rare lysosomal storage disorder with ocular motor involvement. In a multicontinental, cross-sectional study we characterized ocular motor function in 72 genetically proven patients from twelve countries by means of video-oculography. Interlinking with disease severity, we also searched for ocular motor biomarkers. Our study protocol comprised reflexive and self-paced saccades, smooth pursuit, and gaze-holding in horizontal and vertical planes. Data were compared with those of 158 healthy controls. The Modified Disability Rating Scale, Scale for Assessment and Rating of Ataxia, Spinocerebellar Ataxia Functional Index for neurological status, and Montreal Cognitive Assessment for cognition were also performed.In contrast to previous publications and the common belief that the “downward saccadic system degenerates to greater extent than the upward one”, our measurements of vertical saccades demonstrated that the involvement in both directions was similar. Mean saccadic peak velocity to 20° stimulus was 63.5°/s (SD, 95% CIs of the mean: 59.5, [47.9-79.2]) in NPC patients and 403.1°/s (69.0, [392.0-414.2°/s]) in healthy subjects (p<0.001). Downward saccades yielded 51°/s (68.9, [32.7-69.3]), whilst upward 78.8°/s (65.9, [60.8-96.8]) (p<0.001). Vertical position smooth pursuit gain was 0.649 (0.33, [0.554-0.744]) in NPC and 0.935 (0.149 [0.91-0.959]) in HC (p<0.001).The number of patient-specific saccadic patterns, incl. slow-pursuit like, hypometric and staircase-pattern saccades suggest varying involvement of the saccadic system with fragmentation of the velocity profile as a sign of omnipause neuron dysfunction. Observed compensating strategies, such as blinks to elicit saccades, head and upper body movements to overcome the gaze palsy, should be used clinically to establish a diagnosis.Vertical reflexive saccades were more impaired and slower than self-paced ones. Ocular motor performance depended on age of onset and disease duration.We found that peak velocity and latency of horizontal saccades, vertical saccadic duration and amplitude, and horizontal position smooth pursuit can be used as surrogate parameters for clinical trials, as they showed the strongest correlation to disease severity. By comparing saccadic with pursuit movements, we showed that 98.2% of patients generated vertical saccades (both up and down) that were below the 95% confidence intervals of the controls’ peak velocity. Only 46.9% of patients had smooth pursuit gain lower than that of 95% of healthy controls. Vertical supranuclear saccade palsy and not vertical supranuclear gaze palsy is the hallmark of NPC disease. The distinction between saccadic and gaze palsy is also important in other neurodegenerative diseases and inborn errors of metabolism with ocular motor involvement, such as progressive supranuclear palsy or Gaucher disease type 3.Competing Interest StatementDr. Bremova-Ertl received honoraria for lecturing from Actelion and Sanofi-Genzyme. Dr. Abel received consultant fees from Actelion. Dr. Walterfang has received consulting fees and speakers honoraria from Actelion, Lilly, Pfizer, Biomarin, Orphazyme, Mallinkrodt, Shire, Idorsia, Janssen and Lundbeck Pharmaceuticals. Dr. Ardissone, Dr. Amraoui, Dr. Kolnikova and Dr. Ashrafi report no disclosures. Dr. Malinova received speakers honoraria from Actelion, Sanofi-Genzyme, Shire and Synageva. Dr. Salsano received consulting fees from Actelion. Dr. Tavasoli received honoraria for lecturing from Actelion. Dr. Mengel received research grants, speakers honoraria and consultant fees from Actelion, Sanofi-Genzyme, BioMarin, Takeda-Shire, Orphazyme, Idorsia and Alexion. Dipl-Ing. Bardins received speakers honoraria for lecturing from Actelion, he is shareholder of EyeSeeTec GmbH, manufacturer of the eye-tracking equipment used in the study. M. Strupp is Joint Chief Editor of the Journal of Neurology, Editor in Chief of Frontiers of Neuro-otology and Section Editor of F1000. He has received speakers honoraria from Abbott, Actelion, Auris Medical, Biogen, Eisai, Gruenenthal, GSK, Henning Pharma, Interacoustics, Merck, MSD, Otometrics, Pierre-Fabre, TEVA, UCB. He is a shareholder of IntraBio. He acts as a consultant for Abbott, Actelion, AurisMedical, Heel, IntraBio and Sensorion.Funding StatementThis study was supported by Actelion, Ltd, a Janssen company of Johnson & Johnsons.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was performed in accordance with the Helsinki II Declaration and approved by the ethics committee of the Ludwig Maximilian University Medical Faculty (addendum to project no 379-12). All participants or their legal guardians gave their informed consent prior to their inclusion in the study.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets used and analyzed during the presented study are available from the corresponding author upon reasonable request.